SEATTLE – A new study from Fred Hutchinson Cancer Research Center reveals what may be the earliest step in the development of prostate cancer. The finding could open the door to new tests that predict whether the cancer will become aggressive and the development of treatments to prevent the condition from progressing.
The study, published in the Sept. 1 issue of Cancer Research, found that when mice are engineered to lose a single copy of a gene called Rb in their prostate, they develop a precancerous condition analogous to the earliest stages of human prostate cancer. Importantly, in the absence of additional genetic defects, the mice do not develop full-blown prostate cancer.
This suggests that the loss of Rb in prostate cells could be the initial spark that in some men eventually leads to prostate cancer, said senior author Norman Greenberg, Ph.D., a member of Fred Hutchinson's Clinical Research Division.
"Finding the loss of Rb is like seeing smoke," he said. "We now need to figure out the genetic predictors for fire."
To identify genetic events that cause early-stage prostate cancer, Greenberg and colleagues focused on the Rb gene. The gene is known to be defective in a variety of cancer types, including up to 60 percent of human prostate cancers. Rb is a member of a family of genes known as tumor suppressors, which normally work to keep cells dividing at a healthy pace. Cells with defective or missing tumor suppressors lose their brakes on cell division, a hallmark of cancer.
The researchers developed a system using mice that were genetically engineered to self-destruct one or both copies of its Rb gene in prostate cells. The important difference between these mice and the standard gene knock-out strategy is that the Rb gene stays intact in all other tissues of the animal, a situation that closely resembles how genes are inactivated or lost in cancers that occur sporadically in humans.
The scientists found that upon losing even one copy of the Rb gene in prostate cells, mice developed a condition known as focal hyperplasia, characterized by precancerous growths. Nearly a year after they formed, the growths did not become cancerous.
"This suggests to us that loss of a single copy of Rb can initiate this excess cell growth but is not sufficient for cancer to develop," Greenberg said. "Perhaps the most significant finding was that loss of the second copy of Rb – an event previously thought to be essential for tumor progression – did not appear to accelerate the disease. Losing one copy was enough to get things going."
While Greenberg had previously demonstrated that combined loss of Rb and related proteins and the p53 tumor suppressor would predispose mice to develop aggressive prostate cancer, the role of Rb in tumor initiation remained enigmatic. Further research is needed to determine which secondary mutations can push these early stage growths into prostate cancer. Greenberg said that tests to distinguish between men who only have Rb mutations and those who have acquired additional genetic defects could help doctors decide when or whether aggressive treatment is warranted.
"Right now, there is no way to absolutely predict at an early stage whether a man's prostate cancer is slow-growing and non-lethal, meaning that many men receive unnecessary treatment that can cause serious side effects," he said.
Scientists have had a difficult time establishing the causal relationship between genes and cancer, Greenberg said. "We've addressed this by using a mouse system that allows us to selectively eliminate genes in the epithelial cells of the prostate. Our experimental approach allows us to closely mimic what happens in man and gives us a glimpse into the natural history of the disease that we haven't had before." Greenberg developed a widely used genetically engineered strain of mice that develops prostate cancer at the Baylor College of Medicine prior to joining Fred Hutchinson in January.
"These models represent a new frontier in cancer research because they give us a better insight into what specific genes really do in a live mammal," he said. "The mice give us a highly reproducible glimpse at the earliest forms of cancer – those rarely seen in the clinic – and therefore can be used to develop new markers for detection as well as new strategies for prevention and early intervention."
Prostate cancer is the second leading cause of death for men in the United States. This year, more than 230,000 men will be diagnosed with the disease, in large part due to widespread screening with the prostate-specific antigen, or PSA, test. The test has been controversial because it cannot distinguish between men who have non-progressing forms of the disease that may never cause harm and those who have aggressive cancers that require treatment. Researchers are eager to develop tests that can stratify early stage prostate cancers by their likelihood to worsen, an achievement that could spare many men from unnecessary surgery or radiation therapy.
With this in mind, Greenberg said his next goal is to identify the additional mutations - such as occur in p53 or other tumor suppressor genes - that must collaborate with Rb to drive the benign condition to cancer. Ideally, blood or other simple tests to detect these mutations could be developed that reveal predictive information about a man's type of cancer well before he is in danger.
"The idea is to set the bar for detection as early as possible," Greenberg said. "Ideally, we'd hope that a man diagnosed at an early age with prostate cancer could be assured that his cancer wasn't likely to progress or that he needed early intervention that could save his life."
The study, funded by the National Cancer Institute and the Prostate Cancer Foundation, was led by Lisette Maddison, Ph.D., a former graduate student of Greenberg's who is now a postdoctoral fellow at Oregon Health and Science University. Other coauthors were Brent Sutherland, Ph.D., a postdoctoral fellow in Greenberg's lab; and Roberto Barrios, a pathologist at Baylor College of Medicine.
Fred Hutchinson Cancer Research Center, home of two Nobel laureates, is an independent, nonprofit research institution dedicated to the development and advancement of biomedical technology to eliminate cancer and other potentially fatal diseases. Fred Hutchinson receives more funding from the National Institutes of Health than any other independent U.S. research center. Recognized internationally for its pioneering work in bone-marrow transplantation, the center's four scientific divisions collaborate to form a unique environment for conducting basic and applied science. Fred Hutchinson, in collaboration with its clinical and research partners, the University of Washington Academic Medical Center and Children's Hospital and Regional Medical Center, is the only National Cancer Institute-designated comprehensive cancer center in the Pacific Northwest and is one of 38 nationwide. For more information, visit the center's Web site at http://www.fhcrc.org.
Cite This Page: